Moleculin Biotech, Inc. — Form S-1/A
Filed July 30, 2026 · analyzed by the Registration Agent
S-1/A
▲ Likely positive
significance 72/100
What the filing says
Moleculin Biotech filed an S-1/A for a best-efforts registered direct offering of up to 4.6M shares at $2.19/share, plus up to 13.7M common warrants (3 per share, 5-year term, $2.19 exercise price) and up to 4.6M pre-funded warrants ($0.001 exercise price). Placement agent: Roth Capital Partners (7% commission). Net proceeds estimated at ~$9.1M (before warrant exercise) if fully subscribed; capital intended for Annamycin (naxtarubicin) Phase 2/3 trial and working capital. Company reported June 2026 interim MIRACLE trial data: 43–50% CR/CRc rates (Annamycin arms) vs. 12–29% (control); iDMC approved continuation. No minimum subscription; offering terminates August 14, 2026. Market cap ~$8.8M; public float ~$7.1M shares as of June 30, 2026.
Why this rating
Offering represents ~103% of current market cap; material dilution (74% share count increase). Trial interim data supportive but pre-statistical-significance. Capital critical for Phase 2/3 continuation; 'best efforts' structure risks undersubscription. Positive trial trend outweighed by execution risk and leverage.
Extracted items
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.